DelveInsight’s, “Pulmonary Hypertension Pipeline Insight 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Pulmonary Hypertension pipeline landscape. It covers the Pulmonary Hypertension pipeline drug profiles, including Pulmonary Hypertension clinical trials and nonclinical stage products. It also covers the Pulmonary Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Pulmonary Hypertension Pipeline Insight Report
Recent Developmental Activities in the Pulmonary Hypertension Treatment Landscape
Discover the recent advances in pulmonary hypertension treatment drugs @ Pulmonary Hypertension Pipeline Outlook
Pulmonary Hypertension Overview
Pulmonary hypertension (PH), is a complex and often misunderstood disease. The term PH means high blood pressure in the lungs. In “regular” hypertension (also known as high blood pressure or “systemic hypertension) the pressure in the arteries throughout the body is higher than it should be. This can be measured with a blood pressure cuff. In PH, the blood vessels specifically in the lungs are affected. They can become stiff, damaged or narrow, and the right side of the heart must work harder to pump blood through. Each form of PH is different, so it is important for newly-diagnosed patients to find a PH specialist who can accurately find what is causing their PH and develop a treatment plan that is right for that specific type of PH as soon as possible.
Pulmonary Hypertension Emerging Drugs
Ralinepag: Arena Pharmaceuticals/United Therapeutics
Ralinepag (APD811) is a next-generation, oral, selective potent, once-daily IP receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). Arena discovered and developed this drug candidate internally. Ralinepag’s potency on vasodilation, inhibition of proliferation of vascular smooth muscle cells, and inhibition of platelet aggregation, combined with an extended half-life, support its application as a potentially best-in-class agent for the treatment of PAH. Ralinepag is an investigational compound that is not approved for any use in any country.
Sotatercept: Acceleron Pharma
Sotatercept is an investigational reverse-remodeling agent designed to be a selective ligand trap for members of the TGF-beta superfamily to rebalance signaling in the BMP pathway, which is a key molecular driver of PAH. In preclinical studies, sotatercept was shown to reverse the vascular remodeling that is a hallmark of PAH. Sotatercept is an investigational therapy that is not approved for any use in any country. Sotatercept is part of a licensing agreement with Bristol Myers Squibb.
Zamicastat: Bial – Portela C S.A.
Zamicastat is a reversible dopamine β-hydroxylase (DβH) inhibitor that modulates sympathetic drive by preventing the conversion of dopamine to norepinephrine (NE) in sympathetically innervated tissues. Sympathetic nervous system (SNS) activation contributes to clinical deterioration in pulmonary arterial hypertension. It can cross the blood-brain barrier (BBB) to cause central as well as peripheral effects. Zamicastat is also a concentration-dependent dual P-gp and BCRP inhibitor with IC50 values of 73.8 μM and 17.0 μM, respectively. Zamicastat tends to reduce high blood pressure.
Tocilizumab: Roche
Tocilizumab is a drug which blocks the action of Interleukin-6 and blocking Interleukin-6 has been shown to be effective in animal models of PAH. Tocilizumab was demonstrated to be safe and effective in trials in other diseases associated with PAH, such as rheumatoid arthritis. It is an IL6 receptor–blocking antibody that is currently approved for the treatment of rheumatoid arthritis. It has a side‐effect profile that includes increased risk of infection, elevated levels of total cholesterol and low‐density lipoproteins, liver function abnormalities, and gastrointestinal side effects.
AER-901: Aerami Therapeutics
AER-901 has been developed as a nebulized formulation to improve drug uptake and dosing consistency and to avoid or reduce commonly seen issues related to powdered forms for inhalation including cough, which would be problematic in this group of patients who suffer severe shortness of breath. AER-901 is designed to deliver consistent, therapeutically effective, and well tolerated levels of imatinib through once-a-day inhalation via the Fox device, licensed from Vectura Group plc, which is both 510k cleared and CE marked. The Company is currently investigating AER-901 in healthy adult volunteers in an ongoing phase I trial.
ABI-009: Aadi Biosciences
Aadi’s lead product ABI-009 (sirolimus albumin-bound nanoparticles for injectable suspension) is an mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation and improved efficacy over other mTOR inhibitors in preclinical models. mTOR as a therapeutic target is well recognized in oncology, however Aadi aims to develop the full potential of albumin-bound sirolimus in therapeutic areas and diseases that are driven by mTOR activation and where the mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety or effective targeting to the disease site. It is currently being investigated in Phase I stage of development for the treatment of Pulmonary Arterial Hypertension.
Find out more about pulmonary hypertension drugs in the report @ Pulmonary Hypertension Treatment Landscape
Pulmonary Hypertension Therapeutic Assessment
There are approx. 80+ key companies which are developing the therapies for Pulmonary Hypertension. The Pulmonary Hypertension Companies which have their Pulmonary Hypertension drug candidates in the most advanced stage, i.e. phase II include, Akaza Bioscience.
Pulmonary Hypertension Therapeutics Segmentation
The pulmonary hypertension pipeline report proffers an integral view of the pulmonary hypertension emerging novel therapies segmented by stage, product type, molecule type, Mechanism of action, and route of administration.
Learn more about the novel and emerging pulmonary hypertension pipeline therapies @ Pulmonary Hypertension Ongoing Clinical Trials
Scope of the Pulmonary Hypertension Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Dive deep into rich insights for drugs for pulmonary hypertension treatment, visit @ Pulmonary Hypertension Key Companies and Therapies
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/brucellosis-market